<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546818</url>
  </required_header>
  <id_info>
    <org_study_id>SAV-CT01</org_study_id>
    <nct_id>NCT01546818</nct_id>
  </id_info>
  <brief_title>Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients</brief_title>
  <official_title>A Phase I, Randomized, Observer-blinded, Placebo-controlled Clinical Study to Assess the Safety, Tolerability, and Immune Response of Killed-Whole HIV-1 Vaccine (SAV001-H) Administered Intramuscularly to Chronic HIV-1 Infected Patients Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumagen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety, tolerability, and immune response to
      killed-whole HIV-1 (SAV001-H) vaccine as a primary vaccination regimen in HIV infected
      individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of at least one Grade 3 or higher adverse event, including signs/symptoms, lab toxicities, and/or clinical events possibly or definitely related to study treatment</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immune response of killed-whole HIV-1 (SAV001-H) administered intramuscularly in individuals with chronic HIV-1 infection on HAART</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">33</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SAV001-H</intervention_name>
    <description>A whole-killed HIV</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected

          -  Chronic HIV infection as defined by documentation of HIV infection for over ne year.

          -  Prior antiretroviral therapy defined as a minimum of 6 months of treatment with HAART.
             (HAART is defined as a combination of at least 2 antiretroviral agents.)

          -  CD4+ cell count more than 350 cells per mm3 for a period of 6 months prior to study
             entry at least at 3 different time points (one of which must be obtained at screening)
             obtained at any laboratory that possesses a CLIA certification or its equivalent.

          -  HIV-1 RNA levels less than 50 copies per mL for a period of 6 months prior to study
             entry at least at 3 different time points (one of which must be obtained at screening)
             by any laboratory that possesses a CLIA certification or its equivalent.

          -  Laboratory values obtained within 28 days prior to study entry

          -  Men and women between 18 and 50 years of age

          -  Female study volunteers of reproductive potential (defined as girls who have reached
             menarche or women who have not been post-menopausal for at least 24 consecutive
             months, i.e. who have had menses within the preceding 24 months, or have not undergone
             surgical sterilization (e.g. hysterectomy, bilateral oophorectomy, or salpingotomy)
             must have a negative serum or urine pregnancy test performed within 3 days before
             initiating study-specified medication.

        If participating in sexual activity that could lead to pregnancy, the female study
        volunteer must use a form of contraception listed below while receiving protocol-specified
        medication and for 6 months after stopping the medication. At least one of the following
        methods MUST be used appropriately (with or without hormone-based method):

          -  Condoms (male or female) with or without a spermicidal agent

          -  Diaphragm or cervical cap with spermicide

          -  IUD

               -  Informed of, and willing and able to comply with, the investigational nature of
                  the study, and have signed an informed consent form in accordance with
                  institutional and regulatory guidelines

        Exclusion Criteria:

          -  History of serious adverse reactions to vaccines including anaphylaxis and related
             symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain,
             except for subjects who have a history of an adverse reaction to pertussis vaccine as
             a child may enroll.

          -  History of CD4+ counts less than 350 cells per mm3, opportunistic infections, or
             AIDS-defining illnesses.

          -  History of autoimmune disease, immunodeficiency (other than HIV infection), asthma,
             diabetes (including Type II diabetes or insulin resistance) requiring insulin or oral
             hypoglycemics, thyroid disease, bleeding disorder, active malignancy, viral hepatitis,
             or asplenia.

          -  HBVsAg, HCV Ab, or RPR positive.

          -  Suspected allergy or adverse reaction to any components of the study agent.

          -  Changes in antiretroviral regimen within 6 months prior to entry due to virologic
             failure (not including toxicities).

          -  Pregnancy or breast-feeding.

          -  Receipt of live attenuated vaccines or investigational research agents within 30 days
             prior to study entry.

          -  Receipt of blood products within 120 days prior to study entry.

          -  Receipt of immunoglobulin within 60 days prior to study entry.

          -  Receipt of medically indicated subunit or killed vaccines (e.g., influenza,
             pneumococcal, or allergy treatment with antigen injections) within 14 days prior to
             study entry.

          -  Receipt of prior experimental HIV vaccines.

          -  Any investigational antiretroviral agents that are not obtained through expanded
             access.

          -  Receipt of immunosuppressive medications within the past 6 months (e.g.,
             oral/parenteral/inhaled corticosteroids, and/or cytotoxic medications). NOTE: The
             following will be allowed: corticosteroid nasal spray for allergic rhinitis; topical
             corticosteroids for acute, uncomplicated dermatitis; over the counter medications for
             acute, uncomplicated dermatitis for a period not longer than 14 days.

          -  Current anti-TB prophylaxis or therapy.

          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with adherence to study requirements.

          -  Serious illness (requiring systemic treatment and/or hospitalization) until subject
             either completes therapy or is clinically stable on therapy, in the opinion of the
             investigator, for at least 14 days prior to study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony M Mills, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anthony Mills, MD, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Schneider, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Living Hope Clinical Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anthony Mills, MD Internal Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>September 5, 2013</last_update_submitted>
  <last_update_submitted_qc>September 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Vaccine</keyword>
  <keyword>HIV-1 infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

